Commentary: Antiretroviral therapy initiation criteria in low resource settings-from 'when to start' to 'when not to start'

AIDS

Volumn 28, Issue SUPPL. 2, 2014, Pages

  Eholie, Serge Paul ^a,b,c   Vella, Stefano ^d   Anglaret, Xavier ^c,e  

^a University Hospital of Treichville   (Côte d’Ivoire)

^b UNIVERSITÉ FÉLIX HOUPHOUËT BOIGNY   (Côte d’Ivoire)

^c ANRS   (Côte d’Ivoire)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^e UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADOLESCENT DISEASE; ANTIVIRAL THERAPY; BRAZIL; CD4+ T LYMPHOCYTE; CHILDHOOD DISEASE; EVIDENCE BASED PRACTICE; FRANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORTALITY; NOTE; PRIORITY JOURNAL; UNITED STATES; WORLD HEALTH ORGANIZATION; HIV INFECTIONS;

ANTI-RETROVIRAL AGENTS; HIV INFECTIONS; HUMANS;

EID: 84901429977     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000237     Document Type: Note

References (34)

1. WHO, UNICEF, UNAIDS. Global update on HIV treatment 2013: results, impact and opportunities. www.who.int/hiv/pub/progressreports/update2013/en. [Accessed 26 January 2014]
2. Mills EJ, Bakanda C, Birungi J, Mwesigwa R, Chan K, Ford N, et al. Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda. AIDS 2011; 25:851-855.
3. Oliveira I, Andersen A, Furtado A, Medina C, da Silva D, da Silva ZJ, et al. Assessment of simple risk markers for early mortality among HIV-infected patients in Guinea-Bissau: a cohort study. Br Med J 2012; 2:pii e001587.
4. Fox MP, Shearer K, Maskew M, Macleod W, Majuba P, Macphail P, et al. Treatment outcomes after 7 years of publicsector HIV treatment. AIDS 2012; 26:1823-1828.
5. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22:1897-1908.
6. Anglaret X, Minga A, Gabillard D, Ouassa T, Messou E, Morris B, et al. AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d'Ivoire. Clin Infect Dis 2012; 54:714-723.
7. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach (2006 revision). Geneva: World Health Organization; 2006, http://www.who.int/hiv/pub/ guidelines/artadultguidelines.pdf. [Accessed 26 January 2014]
8. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach [2010 revision]. Geneva: World Health Organization; 2010, http://whqlibdoc.who.int/ publications/2010/9789241599764-eng.pdf. [Accessed 26 January 2014]
9. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization; 2013, www.who.int/hiv/pub/guidelines/arv2013. [Accessed 26 January 2014]
10. Ministère des Affaires Sociales et de la Santé , Conseil National du Sida, Agence nationale de Recherches sur le SIDA et les Hépatites Virales. Prise en Charge Médicale des Personnes Vivant Avec le VIH. Recommandationsdu Groupe d'Experts. Rapport 2013. http://www.sante.gouv.fr/IMG/pdf/Rapport-Morlat-2013-Mise-en-ligne.pdf. [Accessed 26 January 2014]
11. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://aidsinfo.nih.gov/ contentfiles/lvguide lines/adultandadolescentgl.pdf. [Accessed 26 January 2014]
12. Thompson MA, Aberg JA, Hoy JF, Talenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. J Am Med Assoc 2012; 308:387-402.
13. Ministério de Saúde, Departamento de DST, Aids e Hepatites Virais. Poratdoes do HIV receberäo medicamentos logo que o resultado for confirmado. http://www.aids.gov.br/noticia/2014/portadores-do-hiv-receberao- medicamentos-logo-que-o-resultado-confirmado. [Accessed 23 January 2014]
14. European AIDS Clinical Society Guidelines, version 7.0, October 2013. http://www.eacsociety.org/Portals/0/Guidelines-Online-131014.pdf. [Accessed 23 January 2014]
15. Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013). http://onlinelibrary. wiley.com/doi/10.1111/hiv.12119/pdf.
16. Moh R, Danel C, Messou E, Ouassa T, Gabillard D, Anzian A, et al. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa. AIDS 2007; 21:2483-2491.
17. Severe P, Juste MA, Ambroise A, Eliacin L, Marchand C, Apollon S, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010; 363:257-265.
18. Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197:1133-1144.
19. Gabillard D, Lewden C, Ndoye I, Moh R, Segeral O, Tonwe-Gold B, et al. Mortality, AIDS-morbidity, and loss to follow-up by current CD4 cell count among HIV-1-infected adults receiving antiretroviral therapy in Africa and Asia: data from the ANRS 12222 collaboration. J Acquir Immune Defic Syndr 2013; 62:555-561.
20. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493-505.
21. Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 2013; 339:966-971.
22. Jean K, Gabillard D, Moh R, Danel C, Fassassi R, Desgrées-du- Loû A, et al. Effect of early antiretroviral therapy on sexual behaviors and HIV-1 transmission risk among adults with diverse heterosexual partnership statuses in Cote d'Ivoire. J Infect Dis 2014; 209:431-440.
23. Anglemyer A, Rutherford GW, Easterbrook PJ, Horvath T, Vitó ria M, Jan M, Doherty MC. Early initiation of antiretroviral therapy in HIV-infected adults and adolescents: a systematic review. AIDS 2014; 28 (Suppl 2):S105-S118.
24. Alexander PE, Bero L, Montori VM, Britog JP, Stoltzfush R, Djulbegovic B, et al. World Health Organization recommendations are often strong based on low confidence in effect estimates. J Clin Epidemiol 2014; pii: S0895-4356.
25. Early antiretroviral treatment and/or early isoniazid prophylaxis against tuberculosis in HIV-infected adults (ANRS 12136 TEMPRANO). http:// clinicaltrials.gov/show/NCT00495651. [Accessed 26 January 2014]
26. Strategic Timing of Antiretroviral Treatment (START). http://clinicaltrials.gov/ct2/show/NCT00867048. [Accessed 26 January 2014]
27. Egger M, Ekouevi DK, Williams C, Lyamuya RE, Mukumbi H, Braitstein P, et al. Cohort profile: the international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. Int J Epidemiol 2012; 41:1256-1264.
28. Mugglin C, Estill J, Wandeler G, Bender N, Egger M, Gsponer T, et al. Loss to programme between HIV diagnosis and initiation of antiretroviral therapy in sub-Saharan Africa: systematic review and meta-analysis. Trop Med Int Health 2012; 17: 1509-1520.
29. Govindasamy D, Ford N, Kranzer K. Risk factors, barriers and facilitators for linkage to antiretroviral therapy care: a systematic review. AIDS 2012; 26:2059-2067.
30. Boullé C, Kouanfack C, Laborde-Balen G, Carrieri MP, Dontsop M, Boyer S, et al. Task shifting HIV care in rural district hospitals in Cameroon: evidence of comparable antiretroviral treatment-related outcomes between nurses and physicians in the Stratall ANRS/ESTHER trial. J Acquir Immune Defic Syndr 2013; 62:569-576.
31. Lambdin BH, Micek MA, Koepsell TD, Hughes JP, Sherr K, Pfeiffer J, et al. Patient volume, human resource levels, and attrition from HIV treatment programs in central Mozambique. J Acquir Immune Defic Syndr 2011; 57:e33-e39.
32. Assefa Y, Kiflie A, Tekle B, Mariam DH, Laga M, Van Damme W. Effectiveness and acceptability of delivery of antiretroviral treatment in health centres by health officers and nurses in Ethiopia. J Health Serv Res Policy 2012; 17:24-29.
33. World Health Organization. March 2014 supplement ot the 2013 consolidated guidelines in the use of antiretroviral drugs for treating and preventing HIV infection. World Health Organization; 2014. www.who.int/hiv/pub/guidelines/ arv2013supple ment-march2014/en/. [Accessed 26 January 2014]
34. Ford N, Flexner C, Vella S, Ripin D, Vitoria M. Optimization and simplification of antiretroviral therapy for adults and children. Curr Opin HIV AIDS 2013; 8:591-599.